Sarepta Therapeutics (SRPT) Tops Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Sarepta Therapeutics (SRPT) PT Raised to $96 at H.C. Wainwright
May 7, 2018 8:17 AM EDTH.C. Wainwright raised its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $96.00 (from $90.00) while maintaining a Buy rating following the company's 1Q. During its 1Q18 corporate update, Sarepta also disclosed an exclusive collaboration and investment in Myonexus Therapeutics.
The alliance,... More
Sarepta Therapeutics (SRPT) PT Raised to $109 at Needham & Company
May 7, 2018 6:20 AM EDTNeedham & Company raised its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $109.00 (from $75.00) while maintaining a Buy rating.
Analsyt Chad Messer commented, "Sarepta reported in line 1Q:18 Exondys revenues of $64.6M. Exondys received a negative trend vote in the EU, for which Sarepta... More
Sarepta Therapeutics (SRPT) PT Raised to $98 at RBC Capital
May 4, 2018 8:50 AM EDTRBC Capital raised its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $98.00 (from $91.00) while maintaining an Outperform rating.
Analyst Rick Bienkowski commented, "On the back of solid 1Q Exondys 51 sales reaffirming confidence in 2018 revenues and future DMD franchise growth, and increasing enthusiasm into June's... More
